Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

NCT02682407 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated by Sponsor

Conditions

IgAN
LN
MN
C3G

Interventions

BIOLOGICAL: OMS721 (narsoplimab)

Sponsor

Omeros Corporation